Safety and immunogenicity of a 15-valent pneumococcal conjugate vaccine in Japanese healthy infants: A Phase I study (V114-028)

References

• Tan TQ. Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines. Clin Microbiol Rev. 2012;25:409–8. doi:10.1128/CMR.00018-12.
   PubMed Web of Science ®Google Scholar
• Wahl B, O’brien KL, Greenbaum A, Majumder A, Liu L, Chu Y, Luksic I, Nair H, McAllister DA, Campbell H, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15. Lancet Glob Health. 2018;6:e744–57. doi:10.1016/S2214-109X(18)30247-X.
   PubMed Web of Science ®Google Scholar
• Balsells E, Guillot L, Nair H, Kyaw MH. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a systematic review and meta-analysis. PLoS One. 2017;12:e0177113. doi:10.1371/journal.pone.0177113.
   PubMed Web of Science ®Google Scholar
• Cleary DW, Jones J, Gladstone RA, Osman KL, Devine VT, Jefferies JM, Bentley SD, Faust SN, Clarke SC. Changes in serotype prevalence of Streptococcus pneumoniae in Southampton, UK between 2006 and 2018. Sci Rep. 2022;12:13332. doi:10.1038/s41598-022-17600-6.
   PubMed Web of Science ®Google Scholar
• Takeuchi N, Naito S, Ohkusu M, Abe K, Shizuno K, Takahashi A, Omata Y, Nakazawa T, Takeshita K, Hishiki H, et al. Epidemiology of hospitalised paediatric community-acquired pneumonia and bacterial pneumonia following the introduction of 13-valent pneumococcal conjugate vaccine in the national immunisation programme in Japan. Epidemiol Infect. 2020;148:1–11. doi:10.1017/S0950268820000813.
   Web of Science ®Google Scholar
• Food and Drug Administration. PREVNAR 13 (Pneumococcal 13-valent conjugate vaccine [Diphtheria CRM197 Protein]) prescribing information. 2017 [accessed 2022 Mar 29. https://www.fda.gov/files/vaccines%2C%20blood%20%26%20biologics/published/Package-Insert——Prevnar-13.pdf.
   Google Scholar
• Chang B, Akeda H, Nakamura Y, Hamabata H, Ameku K, Toma T, Miyagi M, Ohnishi M. Impact of thirteen-valent pneumococcal conjugate vaccine on nasopharyngeal carriage in healthy children under 24 months in Okinawa, Japan. J Infect Chemother. 2020;26:465–70. doi:10.1016/j.jiac.2019.12.009.
   PubMed Web of Science ®Google Scholar
• Japan Pediatric Society. Changes in the immunization schedule recommended by the Japan Pediatric Society; 2020 [accessed 2022 Oct 7]. https://www.jpeds.or.jp/uploads/files/2020%20English%20JPS%20Immunization%20Schedule.pdf.
   Google Scholar
• Hu T, Giroux V, Goyette A, Weiss T, Petigara T, Owusu-Edusei K. Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in children in Canada. ISPPD. Virtual; 2020.
   Google Scholar
• Balsells E, Dagan R, Yildirim I, Gounder PP, Steens A, Munoz-Almagro C, Mameli C, Kandasamy R, Givon Lavi N, Daprai L, et al. The relative invasive disease potential of Streptococcus pneumoniae among children after PCV introduction: a systematic review and meta-analysis. J Infect. 2018;77:368–78. 10.1016/j.jinf.2018.06.004.
   PubMed Web of Science ®Google Scholar
• Adam HJ, Golden AR, Karlowsky JA, Baxter MR, Nichol KA, Martin I, Demczuk W, Mulvey MR, Gilmour MW, Hoban DJ, et al. Analysis of multidrug resistance in the predominant Streptococcus pneumoniae serotypes in Canada: the SAVE study, 2011–15. J Antimicrob Chemother. 2018;73:vii12–9. doi:10.1093/jac/dky158.
   PubMed Web of Science ®Google Scholar
• Golden AR, Adam HJ, Zhanel GG. Canadian antimicrobial resistance alliance. Invasive Streptococcus pneumoniae in Canada, 2011-2014: characterization of new candidate 15-valent pneumococcal conjugate vaccine serotypes 22F and 33F. Vaccine. 2016;34:2527–30. doi:10.1016/j.vaccine.2016.03.058.
   PubMed Web of Science ®Google Scholar
• Suga S, Chang B, Asada K, Akeda H, Nishi J, Okada K, Wakiguchi H, Maeda A, Oda M, Ishiwada N, et al. Nationwide population-based surveillance of invasive pneumococcal disease in Japanese children: effects of the seven-valent pneumococcal conjugate vaccine. Vaccine. 2015;33:6054–60. doi:10.1016/j.vaccine.2015.07.069.
   PubMed Web of Science ®Google Scholar
• National Institute for Infectious Diseases. Pneumococcal infections in 2017, Japan. Infect Agents Surveill Rep (IASR). 2018;39:107–08.
   Google Scholar
• Epidemiological information on invasive pneumococcal infections in children and adults research group. Epidemiological situation in 2021; 2021 [accessed 2022 Sep 2]. https://ipd-information.com/?page_id=55.
   Google Scholar
• European Medicines Agency. Vaxneuvance: ePAR - Product Information; 2022 [accessed 2022 Jan 17]. https://www.ema.europa.eu/en/documents/product-information/vaxneuvance-epar-product-information_en.pdf.
   Google Scholar
• Health Canada. VAXNEUVANCE® Product monograph; 2022 [accessed 2022 Aug 26]. https://www.merck.ca/en/wp-content/uploads/sites/20/2022/06/VAXNEUVANCE-PM_E.pdf.
   Google Scholar
• Food and Drug Administration. VAXNEUVANCE; 2022 [accessed 2022 Aug 30]. https://www.fda.gov/vaccines-blood-biologics/vaccines/vaxneuvance.
   Google Scholar
• European Medicines Agency. Prevenar 13 summary of product characteristics; 2021 [accessed 2022 Apr 26]. https://www.ema.europa.eu/en/documents/product-information/prevenar-13-epar-product-information_en.pdf
   Google Scholar
• Bili A, Dobson S, Quinones J, Phongsamart W, Oberdorfer P, Kosalaraksa P, Dagan R, Wilck MB, Vallejos W, Nunn C, et al. 1184. A Phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114 and Prevnar 13™ with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION). Open Forum Infect Dis. 2021;8:S684. doi:10.1093/ofid/ofab466.1376.
   Google Scholar
• Lupinacci RR, O. Wittawatmongkol, J. Jones, J. Quinones, B. Ulukol, R. Dagan, P. Richmond, J E. Stek, L. Romero, S. Koseoglu, G. Tamms, R. McFetridge, J. Li, K. Cheon, L. Musey, N. Banniettis, K. Bickham. A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED). Vaccine (Online ahead of print). 2023. doi:10.1016/j.vaccine.2022.12.054.
   Google Scholar
• Kobayashi M, Farrar JL, Gierke R, Leidner AJ, Campos-Outcalt D, Morgan RL, Long SS, Poehling KA, Cohen AL, Group APVW, et al. Use of 15-valent pneumococcal conjugate vaccine among U.S. children: updated recommendations of the advisory committee on immunization practices—United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:1174–81. doi:10.15585/mmwr.mm7137a3.
   PubMed Web of Science ®Google Scholar
• Saitoh A, Okabe M. Current issues with the immunization program in Japan: can we fill the “vaccine gap”? Vaccine. 2012;30: 4752–56. doi:10.1016/j.vaccine.2012.04.026.
   PubMed Web of Science ®Google Scholar
• Merck & Co., Inc., Rahway, NJ, USA. Study to evaluate the safety, tolerability, and immunogenicity of V114 in healthy Japanese infants (V114-033) [ accessed Nov 12]. https://clinicaltrials.gov/ct2/show/NCT04384107
   Google Scholar
• Carlsson RM, Claesson BA, Kayhty H, Selstam U, Iwarson S. Studies on a Hib-tetanus toxoid conjugate vaccine: effects of co-administered tetanus toxoid vaccine, of administration route and of combined administration with an inactivated polio vaccine. Vaccine. 1999;18: 468–78. doi:10.1016/S0264-410X(99)00238-8.
   PubMed Web of Science ®Google Scholar
• Mark A, Carlsson RM, Granstrom M. Subcutaneous versus intramuscular injection for booster DT vaccination of adolescents. Vaccine. 1999;17: 2067–72. doi:10.1016/S0264-410X(98)00410-1.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. VAXNEUVANCE™ (Pneumococcal 15-valent conjugate vaccine) prescribing information; 2021 [ accessed Aug 10]. http://www.fda.gov/vaccines-blood-biologics/vaccines/vaxneuvance.
   Google Scholar
• Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213–26. doi:10.1002/sim.4780040211.
   PubMed Web of Science ®Google Scholar
• Nolan KM, Zhang Y, Antonello JM, Howlett AH, Bonhomme CJ, Greway R, Green T, de Gorguette d’Argoeuves P, Goldblatt D, Murphy RD. Enhanced antipneumococcal antibody electrochemiluminescence assay: validation and bridging to the WHO reference ELISA. Bioanalysis. 2020;12:1363–75. doi:10.4155/bio-2020-0023.
   PubMed Web of Science ®Google Scholar
• Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26: 404–13. doi:10.1093/biomet/26.4.404.
   Web of Science ®Google Scholar
• Kashiwagi Y, Maeda M, Kawashima H, Nakayama T. Inflammatory responses following intramuscular and subcutaneous immunization with aluminum-adjuvanted or non-adjuvanted vaccines. Vaccine. 2014;32:3393–401. doi:10.1016/j.vaccine.2014.04.018.
   PubMed Web of Science ®Google Scholar
• Cook IF. Subcutaneous vaccine administration – an outmoded practice. Hum Vaccin Immunother. 2021;17: 1329–41. doi:10.1080/21645515.2020.1814094.
   PubMed Web of Science ®Google Scholar
• Japan Pediatric Society. Request for the creation of guidelines for vaccination methods. Welfare Science Council Immunization and Vaccine Subcommittee; 2014. https://www.jpeds.or.jp/uploads/files/a_vaccination_method.pdf.
   Google Scholar
• Iwata S, Takata M, Morozumi M, Miyairi I, Matsubara K, Ubukata K, Pneumococcal Meningitis Surveillance Study Group. Drastic reduction in pneumococcal meningitis in children owing to the introduction of pneumococcal conjugate vaccines: longitudinal analysis from 2002 to 2016 in Japan. J Infect Chemother. 2021;27:604–12. doi:10.1016/j.jiac.2020.11.019.
   PubMed Web of Science ®Google Scholar
• Shinjoh M, Yamaguchi Y, Iwata S. Pediatric bacterial meningitis in Japan, 2013-2015 - 3-5 years after the wide use of Haemophilus influenzae type b and Streptococcus pneumoniae conjugated vaccines. J Infect Chemother. 2017;23:427–38. doi:10.1016/j.jiac.2017.02.014.
   PubMed Web of Science ®Google Scholar
• Platt HL, Greenberg D, Tapiero B, Clifford RA, Klein NP, Hurley DC, Shekar T, Li J, Hurtado K, Su SC, et al. A phase II trial of safety, tolerability and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in healthy infants. Pediatr Infect Dis J. 2020;39:763–70. doi:10.1097/INF.0000000000002765.
   PubMed Web of Science ®Google Scholar